Institutional members access full text with Ovid®

Share this article on:

Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease

Palacios, Santiago MD1; Neyro, José Luis MD2; Puertas, José Chaves PhD3; Fernandez de Cabo, Susana PhD3

doi: 10.1097/GME.0b013e318280a2f6
Original Articles

Objective: GINERISK was designed to assess the clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and to establish the presence of other risk factors.

Methods: In this Spanish cross-sectional, epidemiological, observational study, gynecologists sequentially invited postmenopausal women with osteoporosis under their care to complete a predefined questionnaire during a routine visit. Risk factors for bone fractures, endometrial pathology, breast cancer, and cardiovascular disease were assessed.

Results: In addition to being postmenopausal and having diagnosed osteoporosis, 49.8% (2,070/4,157) of eligible participants had one or more risk factors for bone fractures, 96.8% (4,023/4,157) had one or more risk factors for breast cancer, and 83.4% (3,469/4,157) had one or more risk factors for cardiovascular disease. Furthermore, 20.1% (n = 835) of the women presented with high cardiovascular risk, 16.6% (n = 692) were at high risk for bone fractures, and 14.5% (n = 423) were at high risk for developing breast cancer in the next 5 years, whereas only 9.2% (n = 301) of participants were identified as having high endometrial risk.

Conclusions: In addition to the increased risk of bone fractures, women with osteoporosis are also at risk for endometrial pathology, breast cancer, and cardiovascular disease. These risks should be evaluated and taken into consideration when choosing an osteoporosis treatment for postmenopausal women.

From the 1Palacios Institute of Women’s Health and Medicine, Madrid, Spain; 2Service of Obstetrics and Gynecology, Hospital Universitario de Cruces, Baracaldo, Spain; and 3Medical Unit, Pfizer SLU, Madrid, Spain.

Received October 5, 2012; revised and accepted November 29, 2012.

Funding/support: This study was sponsored by Laboratorios Pfizer España (Madrid, Spain). Editorial assistance provided by Danielle Turner (Prism Ideas, Nantwich, UK) was funded by Pfizer Spain.

Financial disclosure/conflicts of interest: J.C.P. and S.F.d.C. are current employees of Pfizer. S.P. has served as symposium speaker and/or advisory board member for Servier, Pfizer, Pierre-Fabre, Bayer Schering Pharma, GSK, and Amgen, and has received research grants and/or consulting fees from Pfizer, Servier, Amgen, Bayer Schering Pharma, and Teva. J.L.N.B. declares no conflicts of interest.

Address correspondence to: Santiago Palacios, MD, Instituto Palacios, Salud y Medicina de la Mujer, Calle Antonio Acuña, 9, 28009 Madrid, Spain. E-mail: ipalacios@institutopalacios.com

© 2013 by The North American Menopause Society.